Progesterone and antiprogesterone (RU 38486) modulation of estrogen-inducible glycoprotein (USP-1) synthesis and secretion in rat uterine epithelial cells.
Endocrinology. 1988 Apr;122(4):1559-64. doi: 10.1210/endo-122-4-1559.
[Binding characteristics of RU 486 with glucocorticoid and progestin receptors].
Fukuoka H, Jimbo T.
Nihon Naibunpi Gakkai Zasshi. 1988 Aug 20;64(8):698-706. doi: 10.1507/endocrine1927.64.8_698.
PMID: 3224726 Japanese.
A large amount of this compound was demonstrated in the nucleus. (author's)...
[Progestogen therapy in the treatment of endometrial cancer--clinical results and mechanism of steroid action].
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):924-8.
PMID: 2968780 Japanese.
The use of medroxyprogesterone acetate (MPA) in therapy of patients with endometrial cancer has been recently examined by the Japan Gynecological Cancer Treatment Group. The response rate of oral MPA was 23.6% (13/55 evaluables) and the average period up to the onset of re …
[Clinical application of an antiprogesterone preparation, RU 486].
Taketani Y, Ishihara T, Go M, Mizuno M.
Rinsho Fujinka Sanka. 1988;42(3):229-33.
PMID: 12286721 Japanese.
Clinical applications of RU 486, antiprogesterone, include regulating menstruation, contragestion, termination of pregnancy, an anti-tumor effect in cases of breast cancer, maturation of uteri treatment in Cushing's syndrome, and an effect on meningioma. RU 486 shows poten …
RU486 inhibits induction of aromatase by dexamethasone via glucocorticoid receptor in cultured human skin fibroblasts.
Nawata H, Ono K, Ohashi M, Kato K, Ibayashi H.
J Steroid Biochem. 1988 Jan;29(1):63-8. doi: 10.1016/0022-4731(88)90377-9.
The order of the strength of competition was RU486 greater than dexamethasone greater than betamethasone greater than prednisolone greater than hydrocortisone. RU486 abolished a specific 8.6 S [3H]dexamethasone binding peak in the cytosol, determined using a sucrose densit …
RU486, a progestin antagonist, binds to progesterone receptors in a human endometrial cancer cell line and reverses the growth inhibition by progestins.
Terakawa N, Shimizu I, Tanizawa O, Matsumoto K.
J Steroid Biochem. 1988 Aug;31(2):161-6. doi: 10.1016/0022-4731(88)90049-0.
The effect of an antiprogestin compound (RU486) on gonadotropin and prolactin release in vivo.
Arakawa S, Ohkawa T, Kambegawa A, Okinaga S, Arai K.
Asia Oceania J Obstet Gynaecol. 1988 Dec;14(4):501-7. doi: 10.1111/j.1447-0756.1988.tb00141.x.
Effect of RU 486 on luteal function in the early pregnant rat.
Kawano T, Okamura H, Tajima C, Fukuma K, Katabuchi H.
J Reprod Fertil. 1988 May;83(1):279-85. doi: 10.1530/jrf.0.0830279.